Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ABC-study
- 02 Jun 2017 Results (n=33) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 11 Dec 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 07 Aug 2014 New trial record